AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
insight
/
details

Impact of Proteomics on Personalized Medicine and Treatment Monitoring

NextEdge Admin

20 Jun 2024

3 min 18 sec

Personalized Medicine,mass spectrometry,microfluidics

Proteomics has fundamentally transformed cancer diagnostics and treatment monitoring by focusing on the study of proteins and their roles within biological systems. Unlike traditional methods such as imaging and biopsies, which can be invasive and prone to errors, proteomic technologies offer precise advantages through the detection of specific protein biomarkers.

A cornerstone of proteomics in cancer lies in its capability to enhance early detection and prognosis assessment. Techniques like enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and flow cytometry enable the identification of proteomic patterns that facilitate the diagnosis of cancer at earlier stages. For instance, cancer antigen 125 (CA-125) is widely employed to monitor ovarian cancer progression, while prostate-specific antigen (PSA) aids in the early detection of prostate cancer.

Advanced proteomic methods such as mass spectrometry, protein arrays, and microfluidics play pivotal roles in advancing cancer diagnosis and personalized treatment strategies. These technologies empower researchers and clinicians to analyze intricate protein interactions, post-translational modifications, and expression profiles specific to different cancer types. Mass spectrometry, with its capability to identify and quantify proteins even in minute amounts, is invaluable for unraveling cancer biology and identifying potential therapeutic targets.

Proteins like PSA for prostate cancer, CA-125 for ovarian cancer, and CEA for colorectal cancer are routinely assessed using ELISA and IHC, providing critical diagnostic and prognostic information. Furthermore, proteins such as HER2 in breast cancer, BRCA1/2 involved in genetic predisposition to breast and ovarian cancers, and Ki-67 as a marker of cell proliferation are analyzed through immunohistochemistry, guiding treatment decisions and patient management strategies. Additionally, proteins like EGFR in lung cancer are evaluated to determine eligibility for targeted therapies, showcasing how proteomic analyses facilitate personalized medicine approaches tailored to individual patient needs.

Moreover, proteomic analyses offer insights into disease progression and treatment responses by monitoring changes in protein biomarkers over time. This enables clinicians to tailor therapies more precisely and evaluate their effectiveness. This approach not only improves patient outcomes by enabling timely interventions but also enhances healthcare efficiency by reducing unnecessary procedures.